DOYLE THOMAS JAMES 4

What Happened

• Thomas J. Doyle, SVP, Finance & Accounting at Kura Oncology (KURA), sold a total of 7,142 shares on January 27, 2026. The sales were executed at $8.46 per share for total proceeds of approximately $60,427.
• The disposition consisted of five transactions: 2,226; 1,114; 695; 2,226; and 881 shares, all marked as sales (open market or private sale). These appear to be routine sell-to-cover trades rather than discretionary market-timing purchases.

Key Details

• Transaction date and price: 2026-01-27 at $8.46 per share (all reported trades).
• Total shares sold: 7,142; total proceeds: ~$60,427.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: Each sale is indicated as a sell-to-cover for tax withholding tied to RSU vesting (RSU grant dates noted in the filing: 1/2/24; 2/16/23; 1/26/22; 1/2/25; 2/7/22).
• Timeliness: Filing dated 2026-01-27 for transactions on 2026-01-27 — appears timely based on the provided accession info.
• Transaction code: S = Sale; the trades were for tax withholding (routine).

Context

• Sell-to-cover sales are common when restricted stock units vest: the company or insider sells a portion of vested shares to cover taxes. These transactions typically reflect tax obligations, not necessarily a view on the company’s prospects.
• No purchases or option exercises were reported in this filing; the activity reduces the insider’s share count by the amounts listed.